The Salvador-Warts-Hippo pathway controls cell fate and tissue growth. The main function of the Hippo pathway is to prevent YAP and TAZ translocation to the nucleus where they induce the transcription of genes involved in cell proliferation, survival, and stem cell maintenance. Hippo signaling is thus a complex tumor suppressor, and its deregulation is a key feature in many cancers. Recent mounting evidence suggests that the overexpression of Hippo components can be useful prognostic biomarkers.
Background
The Salvador-Warts-Hippo pathway (known as Hippo pathway) was first discovered to be involved in controlling tissue growth in Drosophila Melanogaster in 2002, and it has recently emerged as a critical tumor suppressor network (1) . The Hippo pathway is a highly evolutionarily conserved pathway that controls multiple functions that are crucial to several carcinogenesis processes such as proliferation, apoptosis and stem cell maintenance.
The core of the mammalian Hippo pathway consists of a protein complex that includes: kinases MST1 and MST2 (also known as STK4 and ii) Polarization and Adhesion proteins including those controlling basolateral polarity like the SCRIBBLE complex (6) , apical polarity like CRUMBS complex For more detailed information on Hippo upstream regulators and downstream effectors, we refer the reader to some of the excellent reviews previously published (8, 11) .
Clinical-Translational Advances
Disruptions in the correct function of this pathway have been found to take part in several tumorigenesis mechanisms. However, in human cancer, mutations in the Hippo components are infrequent (12) . The most established mutation is located in the tumor suppressor NF2, an upstream Hippo regulator, causing the autosomal dominant syndrome Type 2 neurofibromatosis that entails, among others the development of meningiomas and schwanomas (13) . In addition, mutations and deletions in LATS2 can be frequently found in malignant mesothelioma (14) . In mice, mutations in Hippo components lead to developmental deficiencies within the intestinal epithelium, liver or skin keratinocytes (15) (16) (17) . Although YAP/TAZ activating mutations have not been described, high YAP/TAZ nuclear levels are present in several cancer types (18). High YAP/TAZ nuclear levels favor cell proliferation and survival as well as the acquisition of a cancer-promoting phenotype. Stem cell maintenance is intimately linked to Hippo signaling in tumor cells. In breast tumors, in vitro studies show how TAZ acts as a stem cell promoter, providing stem cells with self-renewal and tumor initiating capacity. This property is acquired in part by forming a complex with the polarity complex SCRIBBLE that leads to induction of the epitheliummesenchymal-transition (EMT) (6 Hippo activation (33) . In colon cancer, AREG expression is associated with the prognosis of KRAS wild-type patients treated with anti-EGFR therapies. In KRAS mutant patients, Rassf1a activity through Hippo signaling might also be of critical importance as mutant KRAS binds directly to Rassf1 to activate Hippo signaling and promotes apoptosis through p53 (34) . In esophageal cancer, YAP1 has been shown to induce EGFR overexpression leading to chemotherapy resistance (35) . Moreover, in pancreatic KRAS mutant mice models, YAP was found to be an essential oncogenic KRAS effector (36) .
Hippo also regulates the other EGFR downstream branch PI3K-AKT-mTOR (37).
Research. Hippo signaling is also involved in one of the key processes that favor tumor progression, angiogenesis. It is believed that intratumor hypoxia increases the percentage of breast cancer stem cells. This molecular mechanism is not well understood but could be explained, in part, by the fact that hypoxic conditions regulate TAZ and YAP in cancer cells (38) . The hypoxia hallmark HIF1-α binds directly to WWTR1 gene (that codifies for TAZ) activating the TAZ mRNA transcription which helps maintain a stem cell phenotype (39) . In bone metastasis samples from breast cancer, HIF1-α has been described to co-localize with TAZ in the nucleus. Under hypoxic conditions, nuclear HIF1-α and TAZ favor tumorigenesis by leading to increased transactivation by HIF1-α DNA binding (40) . This increased rate of gene expression likely affects several target genes. Angiopoetin-2, an important angiogenesis regulator, has recently been found to be one of the YAP transcriptional targets in vitro and in vivo (41) . Hippo by exporting YAP/TAZ from the nucleus (58) . Interestingly, the SREBP/mevalonate cascade is needed to activate RhoGTPase. As this metabolic pathway is inhibited by statins, simvastatin has also been reported to repress TAZ, leading to potent anti-cancer effects (20, 59).
Conclusions
The importance of Hippo signaling deregulation in several mechanisms involved in cancer development, progression and resistance to cancer Overall, the Hippo pathway is the newest and probably the most complex tumor suppressor. Better understanding Hippo signaling and modulation will surely lead to new therapeutic approaches against cancer.
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